/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2022-11-30 00:00:412023-03-24 17:26:58iECURE Raises $65 Million to Advance In Vivo Gene Editing Programs for the Treatment of Rare Pediatric Liver Diseases
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2022-10-19 08:00:312023-03-24 17:28:32Preclinical Data from iECURE’s GTP-506 Demonstrates Potential for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2022-09-02 20:04:532023-03-24 17:30:23iECURE Receives FDA Orphan Drug Designation for GTP-506, an Investigational Gene Editing Product Candidate for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
/wp-content/uploads/iEcure_logo.png00eallison/wp-content/uploads/iEcure_logo.pngeallison2022-08-22 19:18:032023-03-24 17:37:04iECURE Receives FDA Rare Pediatric Disease Designation for GTP-506, an Investigational Gene Editing Product Candidate for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2022-05-25 05:00:362022-05-25 08:00:43iECURE Enters Agreement with Center for Breakthrough Medicines (CBM) to Supply Materials for Future Clinical Programs
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2022-05-18 08:00:012022-05-18 08:16:53Nonhuman Primate Data from iECURE’s Knock-in In Vivo Gene Editing Approach for Deadly Urea Cycle Disorder to be Presented in Presidential Symposium at ASGCT 2022
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2022-05-02 19:02:112022-05-10 20:51:39iECURE Announces Presentation of Data on its Gene Editing Approach at the American Society of Cell and Gene Therapy Annual Meeting
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2022-04-25 07:00:042022-05-10 20:48:21iECURE Appoints George Diaz, M.D., Ph.D., as VP, Therapeutic Area Lead for Urea Cycle Disorders
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2022-02-01 08:11:062022-02-08 20:32:34iECURE Expands Leadership Team with the Appointment of Mark Semanick as VP and Head of Technical Operations and Brad Dickerson as VP of Project Management & Patient Advocacy
/wp-content/uploads/iEcure_logo.png00eallison/wp-content/uploads/iEcure_logo.pngeallison2021-12-16 08:00:052022-05-10 20:07:18iECURE Partners to Develop Next-Generation Liver-Targeted Lipid Nanoparticles with University of Pennsylvania
